Saturday, July 11, 2026

Drug profile · INN

zilovertamab

zilovertamab is a inactive tyrosine-protein kinase transmembrane receptor ror1 inhibitor.

NMPA: clinical trials
Patents linked 0
Pipeline programs 5
News articles 0
Drug details — zilovertamab
Class
Route
Patents
0
Programs
5
Data quality
0.70

Quick answer

zilovertamab is a inactive tyrosine-protein kinase transmembrane receptor ror1 inhibitor.

Key facts

INN zilovertamab
Mechanism Inactive tyrosine-protein kinase transmembrane receptor ROR1 inhibitor
Target Inactive tyrosine-protein kinase transmembrane receptor ROR1

Mechanism of action

Inactive tyrosine-protein kinase transmembrane receptor ROR1 inhibitor

Primary target: Inactive tyrosine-protein kinase transmembrane receptor ROR1

Approval history

Authority Status Date
NMPA clinical trials

Pipeline programs

  1. MK-2140-010 Phase 3 · MSD Merck Sharp · Diffuse Large B-Cell Lymphoma (DLBCL)
  2. Zilovertamab vedotin Phase 3 · Merck KGaA, Darmstadt · Diffuse Large B-Cell Lymphoma
  3. MK-2140-006 Phase 2 · MSD Merck Sharp · Aggressive and Indolent B-cell Malignancies (mantle cell lym
  4. MK-2140-011 Phase 2 · MSD Merck Sharp · Diffuse Large B-Cell Lymphoma (DLBCL)
  5. Zilovertamab vedotin Phase 2 · MSD Merck Sharp · Hematologic Malignancies or Solid Tumors in Pediatric and Yo

Frequently asked questions

What is zilovertamab?

zilovertamab is a inactive tyrosine-protein kinase transmembrane receptor ror1 inhibitor.